Letrozole(Femara)

Letrozole(Femara)
CAS No： 112809-51-5
Molecular formula： C17H11N5
Molecular weight： 285.3
Appearance： White power
Assay： 99 percent
Delivery time： 5-7working days door to door
Minimum order： 1g
Supply ability： 100kg/month
Quality standard： USP32                                                                                                                            Detail：
Letrozole is approved by the United States Food and Drug Administration (FDA) for the treatment of local or metastatic breast cancer that is hormone receptor positive or has an unknown receptor status in postmenopausal women.

 Letrozole is intended for use only by women who are no longer of childbearing age. Possible candidates must have already ceased to menstruate. It is often used in patients who have already undergone other cancer treatments, such as radiation, chemotherapy, and used other cancer drugs, like tamoxifen. This nonsteroidal aromatase inhibitor may help prevent any remaining cancer cells from spreading.